The company is now preparing for the next stage of the Phase II trial, which will focus on elderly patients.
BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today announced that it has successfully completed the Phase IIa clinical trial to test the safety and immune response of its universal flu vaccine, Multimeric-001. The trial met all its endpoints: it was found to be safe and caused a strong immune response.
The trial included 200 persons at two Israeli medical centers. This was the third clinical trial that BiondVax has conducted on its universal flu vaccine. Previous trials on people aged 18-49 and on 55-75 were both successful. The company is now preparing for the next stage of the Phase II trial, which will focus on elderly patients, a group that is at high risk of flu, and for whom the effectiveness rate of current commercial vaccines is low. The trial at two Israeli medical centers will include 110 men and women over 65. It will begin in the fourth quarter of 2011 and end in the first quarter of 2012.
BiondVax's share price rose 6.1% in morning trading to NIS 2.17, giving a market cap of NIS 81 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 16, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011